Owen Patrick Smith
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Owen Patrick Smith has a total of 97 co-authors. Here are the top co-authors by number of shared publications:
- Aengus O'Marcaigh
Department of Haematology, Our Lady's Children's Hospital, Dublin, Ireland
6 shared publications Lorna Storey
National Children’s Cancer Service, Children’s Health Ireland at Crumlin, Dublin, Ireland
6 shared publicationsAndrea Malone
National Children’s Cancer Service, Children’s Health Ireland at Crumlin, Dublin, Ireland
5 shared publicationsJonathan Bond
National Children’s Cancer Service, Children’s Health Ireland at Crumlin, Dublin, Ireland
4 shared publicationsPeter McCarthy
National Children’s Cancer Service, Children’s Health Ireland at Crumlin, Dublin, Ireland
4 shared publications- Alan D. Irvine
Department of Clinical Medicine Trinity College Dublin Dublin Ireland
3 shared publications
Latest Publications
- Open Access
- 18 November 2025
- Published by Springer Nature in Annals of Hematology
- Vol. 104 (12) , 6297-6304
Paediatric lymphoblastic lymphoma: a national review of 20 years of clinical and biological data in Ireland
Lymphoblastic lymphoma (LBL) is a rare, aggressive malignancy comprising T-cell (T-LBL) and B-cell (B-LBL) subtypes. While outcomes for LBL have improved, comprehensive national data on clinical and biological features remain limited. We conducted a retrospective review of children and adolescents with LBL in Ireland over 20 years (2004–2023). Data on demographics, clinical presentation, tumour characterization, treatment protocols, and outcomes were analysed. The cohort included 52 patients: 79% with T-LBL and 21% with B-LBL. T-LBL cases predominantly affected males (2.2:1) and presented with advanced disease, including mediastinal masses (98%) and high lactate dehydrogenase levels. B-LBL cases had a female predominance (0.4:1) and localized disease (82%). Survival outcomes were excellent for B-LBL, with 5-year event-free survival (EFS) and overall survival (OS) of 100%. For T-LBL, 5-year EFS and OS were 85%. Relapsed/refractory disease occurred in 4% (T-LBL only). Genetic, Minimal Disseminated Disease and Minimal Residual Disease analyses were limited. LBL outcomes in Ireland align with international reports, highlighting favourable survival but underscoring the need for improved risk stratification and genetic profiling, particularly for T-LBL.
- 18 November 2025
- Published by Springer Nature in Annals of Hematology
- Vol. 104 (12) , 6297-6304
Open AccessPaediatric lymphoblastic lymphoma: a national review of 20 years of clinical and biological data in Ireland
Lymphoblastic lymphoma (LBL) is a rare, aggressive malignancy comprising T-cell (T-LBL) and B-cell (B-LBL) subtypes. While outcomes for LBL have improved, comprehensive national data on clinical and biological features remain limited. We conducted a retrospective review of children and adolescents with LBL in Ireland over 20 years (2004–2023). Data on demographics, clinical presentation, tumour characterization, treatment protocols, and outcomes were analysed. The cohort included 52 patients: 79% with T-LBL and 21% with B-LBL. T-LBL cases predominantly affected males (2.2:1) and presented with advanced disease, including mediastinal masses (98%) and high lactate dehydrogenase levels. B-LBL cases had a female predominance (0.4:1) and localized disease (82%). Survival outcomes were excellent for B-LBL, with 5-year event-free survival (EFS) and overall survival (OS) of 100%. For T-LBL, 5-year EFS and OS were 85%. Relapsed/refractory disease occurred in 4% (T-LBL only). Genetic, Minimal Disseminated Disease and Minimal Residual Disease analyses were limited. LBL outcomes in Ireland align with international reports, highlighting favourable survival but underscoring the need for improved risk stratification and genetic profiling, particularly for T-LBL.
- 27 June 2024
- Published by Wiley in British Journal of Haematology
- Vol. 205 (2) , 729-732
MRD‐risk stratification mitigates TLX3 prognostic impact in paediatric T‐cell acute lymphoblastic leukaemia: A national cohort analysis
- 27 June 2024
- Published by Wiley in British Journal of Haematology
- Vol. 205 (2) , 729-732
MRD‐risk stratification mitigates TLX3 prognostic impact in paediatric T‐cell acute lymphoblastic leukaemia: A national cohort analysis
- 11 January 2024
- Published by Wiley in International Journal of Cancer
- Vol. 154 (9) , 1669-1674
Comments on “Social inequalities in treatment receipt for childhood cancers in Ireland: A population‐based analysis”
- 11 January 2024
- Published by Wiley in International Journal of Cancer
- Vol. 154 (9) , 1669-1674
Comments on “Social inequalities in treatment receipt for childhood cancers in Ireland: A population‐based analysis”
- Open Access
- 6 October 2022
- Published by Wiley in British Journal of Haematology
- Vol. 199 (2) , 297
Denis Burkitt: A cancer, the virus and the prevention of man‐made diseasesJohn H.CummingsSpringer, 2022. ISBN 978‐3‐03088562‐5, 417 pages, including 130 figures, 6 tables and 4 appendices
- 6 October 2022
- Published by Wiley in British Journal of Haematology
- Vol. 199 (2) , 297
Open AccessDenis Burkitt: A cancer, the virus and the prevention of man‐made diseasesJohn H.CummingsSpringer, 2022. ISBN 978‐3‐03088562‐5, 417 pages, including 130 figures, 6 tables and 4 appendices
- Open Access
- 20 December 2021
- Published by Wiley in British Journal of Haematology
- Vol. 196 (3) , 530-547
Precursor B‐cell acute lymphoblastic leukaemia—a global view
As haematologists, we always seek to follow standardised guidelines for practice and apply the best treatment within our means for our patients with blood diseases. However, treatment can never follow an exact recipe. Opinions differ as to the best approach; sometimes more than one treatment approach results in identical outcomes, or treatments differ only by the manner in which they fail. Furthermore, the haematologist is faced with constraints relating to the local economic environment. Patients too are not the same the world over. Early presentation is commoner in the developed world, as is the patient’s understanding of the disease process. This in turn has an impact on the way patients are managed, the rigorousness of patient adhesion to the treatment schedule and the outcome. Here we take a look at the precursor B-cell acute lymphoblastic leukaemia in an adolescent in a range of different settings from low- to high income countries with widely differing challenges for diagnosis, therpy and follow-up. For these reasons, given the same starting conditions, patients will be treated differently according to the institute and the country they are in. Experts from around the world have been tasked to describe their management plan and rationale for a specific disease presentation. Here they explore the management of precursor B-cell acute lymphoblastic leukaemia (pre-B ALL) in five different institutions worldwide with a focus on those with more or less strained economies. We end with a conclusion from an expert in the field comparing and contrasting these different management styles and considering their merits and limitations.
- 20 December 2021
- Published by Wiley in British Journal of Haematology
- Vol. 196 (3) , 530-547
Open AccessPrecursor B‐cell acute lymphoblastic leukaemia—a global view
As haematologists, we always seek to follow standardised guidelines for practice and apply the best treatment within our means for our patients with blood diseases. However, treatment can never follow an exact recipe. Opinions differ as to the best approach; sometimes more than one treatment approach results in identical outcomes, or treatments differ only by the manner in which they fail. Furthermore, the haematologist is faced with constraints relating to the local economic environment. Patients too are not the same the world over. Early presentation is commoner in the developed world, as is the patient’s understanding of the disease process. This in turn has an impact on the way patients are managed, the rigorousness of patient adhesion to the treatment schedule and the outcome. Here we take a look at the precursor B-cell acute lymphoblastic leukaemia in an adolescent in a range of different settings from low- to high income countries with widely differing challenges for diagnosis, therpy and follow-up. For these reasons, given the same starting conditions, patients will be treated differently according to the institute and the country they are in. Experts from around the world have been tasked to describe their management plan and rationale for a specific disease presentation. Here they explore the management of precursor B-cell acute lymphoblastic leukaemia (pre-B ALL) in five different institutions worldwide with a focus on those with more or less strained economies. We end with a conclusion from an expert in the field comparing and contrasting these different management styles and considering their merits and limitations.
- Open Access
- 22 September 2021
- Published by Wiley in British Journal of Haematology
- Vol. 196 (3) , E39-E42
Autosomal dominant Shwachman–Diamond syndrome with a novel heterozygous missense variant in the SRP54 gene causing severe phenotypic features
- 22 September 2021
- Published by Wiley in British Journal of Haematology
- Vol. 196 (3) , E39-E42
Open AccessAutosomal dominant Shwachman–Diamond syndrome with a novel heterozygous missense variant in the SRP54 gene causing severe phenotypic features
- 8 March 2021
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 62 (8) , 1995-1999
Ongoing excellent outcomes with reduced toxicities following integration of molecular targeted therapies in pediatric anaplastic large cell lymphoma
- 8 March 2021
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 62 (8) , 1995-1999
Ongoing excellent outcomes with reduced toxicities following integration of molecular targeted therapies in pediatric anaplastic large cell lymphoma
- 1 March 2021
- Published by Wiley in British Journal of Haematology
- Vol. 193 (5) , 1013-1014
Memoirs of Victor Hoffbrand (May 2020)
- 1 March 2021
- Published by Wiley in British Journal of Haematology
- Vol. 193 (5) , 1013-1014
Memoirs of Victor Hoffbrand (May 2020)
- 31 January 2020
- Published by Springer Nature in Irish Journal of Medical Science (1971 -)
- Vol. 189 (3) , 979-984
A retrospective study of myeloid leukaemia in children with Down syndrome in Ireland
Background Acute megakaryoblastic leukaemia (AMKL) is a subtype of myeloid leukaemia and is the most common leukaemia type in children with Down syndrome (DS) under 4 years of age. AMKL is often preceded by a transient neonatal pre-leukaemic syndrome, transient myeloproliferative disorder (TMD). Although TMD often spontaneously resolves, 20–30% of these patients subsequently develop AMKL within the first 4 years of life. Aims To perform a retrospective consecutive national audit of all documented cases of childhood TMD and AMKL-DS from 1990 to 2018 at Our Lady’s Children’s Hospital, Crumlin (OLCHC), Ireland. Methods All patients with a diagnosis of AMKL treated consecutively at (OLCHC) between 1990 and 2018 were reviewed. Kaplan-Meier survival curves were constructed. Results Twenty-seven patients with AMKL-DS were identified. A prior neonatal diagnosis of TMD was described in 10 patients (37%). Nineteen patients (70%) are alive and well, in complete remission, at a median follow-up of 11.4 years. Overall survival (OS) of this cohort has risen from 54% from those treated between the years 1990 and 2004 (n = 13) to 93% for those treated between the years 2005 and 2018 (n = 14). Conclusion High cure rates are observed in AMKL-DS using current polychemotherapy protocols. The finding of a low platelet count at time of diagnosis is in keeping with the knowledge that AMKL-DS is a malignancy of platelet progenitor cells.
- 31 January 2020
- Published by Springer Nature in Irish Journal of Medical Science (1971 -)
- Vol. 189 (3) , 979-984
A retrospective study of myeloid leukaemia in children with Down syndrome in Ireland
Background Acute megakaryoblastic leukaemia (AMKL) is a subtype of myeloid leukaemia and is the most common leukaemia type in children with Down syndrome (DS) under 4 years of age. AMKL is often preceded by a transient neonatal pre-leukaemic syndrome, transient myeloproliferative disorder (TMD). Although TMD often spontaneously resolves, 20–30% of these patients subsequently develop AMKL within the first 4 years of life. Aims To perform a retrospective consecutive national audit of all documented cases of childhood TMD and AMKL-DS from 1990 to 2018 at Our Lady’s Children’s Hospital, Crumlin (OLCHC), Ireland. Methods All patients with a diagnosis of AMKL treated consecutively at (OLCHC) between 1990 and 2018 were reviewed. Kaplan-Meier survival curves were constructed. Results Twenty-seven patients with AMKL-DS were identified. A prior neonatal diagnosis of TMD was described in 10 patients (37%). Nineteen patients (70%) are alive and well, in complete remission, at a median follow-up of 11.4 years. Overall survival (OS) of this cohort has risen from 54% from those treated between the years 1990 and 2004 (n = 13) to 93% for those treated between the years 2005 and 2018 (n = 14). Conclusion High cure rates are observed in AMKL-DS using current polychemotherapy protocols. The finding of a low platelet count at time of diagnosis is in keeping with the knowledge that AMKL-DS is a malignancy of platelet progenitor cells.